Besides Wall Street's top-and-bottom-line estimates for Ionis Pharmaceuticals (IONS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Virtual Conference on Thursday, February 26, 2026 TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 Leerink Global Healthcare Conference on Monday, March 9, 2026 Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026 Stifel.
Stratos Wealth Partners LTD. bought a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 7,764 shares of the company's stock, valued at approximately $508,000. A number of other hedge funds and other institutional
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a change in the start time for its fourth quarter and full year 2025 financial results webcast. The live webcast, previously scheduled for 11:30 a.m. Eastern Time, will now be held at 8:30 a.m. Eastern Time on Wednesday, February 25. The date of the call remains unchanged. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limi.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) CEO Brett Monia sold 29,430 shares of the stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $85.79, for a total transaction of $2,524,799.70. Following the sale, the chief executive officer directly owned 254,497 shares in the company, valued
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 25 at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2025 financial results and highlight progress on key programs. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP C Frank Bennett sold 85,089 shares of Ionis Pharmaceuticals stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $82.93, for a total transaction of $7,056,430.77. Following the transaction, the executive vice president directly owned 80,293 shares in the
Insight into Tweedy Browne (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing Tweedy Browne (Trades, Portfolio) recently submitted its 13F filing for the fou
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP Eric Swayze sold 6,179 shares of the firm's stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $82.93, for a total value of $512,424.47. Following the sale, the executive vice president directly owned 47,747 shares in the company,
